Jefferies Upgrades Safran Group Stock with Strong Growth Outlook 
Car dealers took secret fees for recommending finance – and consumers could be owed millions 
Global Smartphone Market Sees Shifts as Chinese Brands Gain Ground 
EU Reassesses Big Tech Probes Under Digital Markets Act 
Teladoc Shares Rise on Amazon Collaboration for Health Programs 
Quantum Computing Stocks Slide as Industry Faces Viability Questions 
Telegram's Latest NFT Update! 
China Tightens Export Scrutiny, Disrupting U.S. Tech Giants' Production Shift 
Rising U.S. Treasury Yields Signal Market Challenges Ahead 
China's Tightened Export Controls Disrupt U.S. Tech Firms' Production Plans 
TikTok Ban Looms as Lawmakers Push for Extended Sale Deadline 
Tesla’s Bullish Future: Morgan Stanley Raises Price Target to $430 
Asian Markets React to Tariff Reports and Fed Policy Shifts 
UniCredit Awaits Credit Agricole’s Decision on Amundi Contract by May 
Blue Origin's New Glenn Rocket Launch Delayed to Thursday 
UBS Predicts Potential Fed Rate Cut Amid Strong US Economic Data 
NVIDIA to Establish Asian Headquarters in Taiwan 
Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 UK Biobank samples. In collaboration with deCODE Genetics, GSK, Novartis, and others, the initiative utilizes Illumina’s next-gen proteomics assay, Protein Prep™, powered by SOMAmer® technology. This solution promises scalable access to proteomic insights, enabling advancements in drug discovery and disease research.
Proteomics, which examines protein functions and biomarkers, supports breakthroughs in cancer, cardiovascular disease, and other conditions. Illumina’s high-throughput Protein Prep technology enhances protein quantitative trait loci (pQTL) discovery, linking genetic variations to protein expression and disease phenotypes.
UK Biobank will contribute 50,000 samples, including 30,000 funded by Illumina, deCODE Genetics, and Standard BioTools. The samples will be processed using NovaSeq™ X Plus and the DRAGEN Protein Quantification pipeline. Data from these samples will be shared with researchers in 2025. For the remaining 20,000 samples, consortium members will receive exclusive access before release to the broader scientific community.
Illumina aims to deliver rich proteomics data to accelerate medical research. “This project will generate high-quality data, advancing biological insights for researchers and pharma partners,” said Steve Barnard, CTO of Illumina.
UK Biobank Principal Investigator Sir Rory Collins praised the program’s potential to enhance understanding of genetics, environment, and lifestyle in disease development. Standard BioTools CEO Michael Egholm highlighted the transformative potential of combining SOMAmer multiplexing with next-gen sequencing.
The Illumina Protein Prep assay detects 9,000 proteins using 11,000 SOMAmer reagents and supports multiomics studies on NovaSeq platforms. Full launch is expected in early 2025.
This pilot marks a milestone in proteomics, fostering collaboration between researchers and industry leaders to advance global healthcare.
